IntroductionGlaucoma is a progressive optic neuropathy that requires continuous monitoring. The purpose of the study was to develop and evaluate the usability of a mobile application, for iOS and Android platforms, containing functionalities to improve patients’ knowledge about glaucoma and facilitate their treatment. MethodsThe application was developed by a multidisciplinary team using an adapted version of a co-design methodology. Thirty-six volunteers were selected, among patients and patients' relatives, from the Instituto Cearense de Oftalmologia, chosen by rational choice sampling, to answer the System Usability Scale after having prior orientation. The results extracted from the questionnaire were analyzed quantitatively. After grouping by age, a proportions test (z-test) was performed. ResultsIt was possible to develop an application for mobile devices named “GlaucoCheck”. Of the 36 interviewees, the average age was 51 (22-69) years old, 56% were women, and 64% had a university degree. The average APP score for usability in the SUS questionnaire was 75.6 (95% CI 74.1-77.2). DiscussionThere was an appropriate acceptance of patients to the “GlaucoCheck”, as it was considered easy to handle, exhibiting interactive and uncomplicated layout. It was possible to develop an application and to register a positive acceptance by the users, encompassing functions that permits better adherence to treatments and additional knowledge about glaucoma.
Purpose: To develop a mobile app that allows photographs to be captured and edited under the overlay of images and projection of a protractor with 360 degrees axis markings, which enables the surgeon to accurately visualize the programmed and marked alignment where the intrastromal corneal ring segments (ICRS) will be implanted, detecting possible marking errors. Methods: A codesign methodology was chosen to develop the Eye Axis Check application. After app development, measurements were obtained, and comparisons were made between manual marks and ICRS alignment with and without the app in 13 eyes that had undergone ICRS implantation for keratoconus. The mobile app was made available to 15 ophthalmic surgeons in different cities to assess its usability. Results: The users approved the developed application for ease of use and utility. No difference was found between the markings made manually and those made with the app, and the mean difference between ICRS centralization and assessment made by the app was 4.84 degrees (95% confidence interval: −5.32 to 15.01; P = 0.3193). On comparison of the agreement between app measurements and manual measurements for the ICRS centration, no significant differences were found, and excellent concordance (0.991) and a strong positive linear correlation (0.984) were observed. Conclusions: A mobile app for preoperative planning and intraoperative ICRS alignment was developed and revealed to be useful and easy to use, allowing the surgeon to visualize the programmed alignment where the ICRS will be implanted.
IntroductionGlaucoma is a progressive optic neuropathy that requires continuous monitoring. The purpose of the study was to develop and evaluate the usability of a mobile application, for iOS and Android platforms, containing functionalities to improve patients' knowledge about glaucoma and facilitate their treatment. MethodsThe application was developed by a multidisciplinary team using an adapted version of a co-design methodology. Thirty-six volunteers were selected, among patients and patients' relatives, from the Instituto Cearense de Oftalmologia, chosen by rational choice sampling, to answer the System Usability Scale after having prior orientation. The results extracted from the questionnaire were analyzed quantitatively. After grouping by age, a proportions test (z-test) was performed. ResultsIt was possible to develop an application for mobile devices named "GlaucoCheck". Of the 36 interviewees, the average age was 51 (22-69) years old, 56% were women, and 64% had a university degree. The average APP score for usability in the SUS questionnaire was 75.6 (95% CI 74.1-77.2). DiscussionThere was an appropriate acceptance of patients to the "GlaucoCheck", as it was considered easy to handle, exhibiting interactive and uncomplicated layout. It was possible to develop an application and to register a positive acceptance by the users, encompassing functions that permits better adherence to treatments and additional knowledge about glaucoma.
This work aims to evaluate the effects of gum arabic and eugenol on inflammatory angiogenesis in a subcutaneous silica inoculum model. Ninety-six Wistar rats were distributed over 16 groups. The substances administered by gavage included distilled water, gum arabic (500 mg/100g weight), and eugenol (10mg/100g weight). Control groups received 0.2 mL of sterile distilled water subcutaneously. The experimental groups were subjected to an inoculum of 0.2 mL of silica solution (50 mg/mL) subcutaneously. For seven or 14 days, the groups received distilled water or gum arabic or eugenol or gum arabic plus eugenol. There was no difference between the histological analysis of slides stained with hematoxylin-eosin. There was a reduction in vascular density in animals that received only gum arabic for 7 (0.09 µm² ± 0.02) or 14 (0.08 µm² ± 0.03) days and only eugenol for seven days (0.08 µm² ± 0.03), but this was not statistically significant. The microvascular density significantly increased in the group treated with eugenol for 14 days (0.14 µm² ± 0.02). Eugenol reduced inflammatory angiogenesis when administered for seven days and stimulated it when administered for 14 days. Gum arabic had a potential inhibitory effect on this model. The study of inflammatory angiogenesis, induced by a silica inoculum in the subcutaneous tissue of rats, is a new and reproducible model for evaluating angiogenesis and inflammation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.